Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding
Autore:
Archer, DF; Dorin, M; Lewis, V; Schneider, DL; Pickar, JH;
Indirizzi:
Eastern Virginia Med Sch, Jones Inst Reprod Med, Dept Obstet & Gynecol, Norfolk, VA 23507 USA Eastern Virginia Med Sch Norfolk VA USA 23507 ecol, Norfolk, VA 23507 USA Univ New Mexico Hosp, Albuquerque, NM 87131 USA Univ New Mexico Hosp Albuquerque NM USA 87131 , Albuquerque, NM 87131 USA Univ Rochester, Med Ctr, Rochester, NY 14642 USA Univ Rochester RochesterNY USA 14642 r, Med Ctr, Rochester, NY 14642 USA Univ Calif San Diego, La Jolla, CA 92093 USA Univ Calif San Diego La Jolla CA USA 92093 Diego, La Jolla, CA 92093 USA Wyeth Ayerst Res, Philadelphia, PA USA Wyeth Ayerst Res Philadelphia PA USA th Ayerst Res, Philadelphia, PA USA
Titolo Testata:
FERTILITY AND STERILITY
fascicolo: 6, volume: 75, anno: 2001,
pagine: 1080 - 1087
SICI:
0015-0282(200106)75:6<1080:EOLDOC>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; ESTERIFIED ESTROGENS; 2-YEAR PERIOD; OSTEOPOROSIS; PREVENTION; ESTRADIOL; PROGESTIN; MENOPAUSE;
Keywords:
conjugated equine estrogens (CEE); medroxyprogesterone acetate (MPA); hormone replacement therapy (HRT); bleeding patterns; lower doses; Women's HOPE study;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Archer, DF Eastern Virginia Med Sch, Jones Inst Reprod Med, Dept Obstet & Gynecol, 601 Colley Ave,Room 142, Norfolk, VA 23507 USA Eastern Virginia Med Sch 601 Colley Ave,Room 142 Norfolk VA USA 23507
Citazione:
D.F. Archer et al., "Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding", FERT STERIL, 75(6), 2001, pp. 1080-1087

Abstract

Objective: To evaluate vaginal breeding profiles with lower doses of conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA) as continuous combined therapy. Design: The Women's Health, Osteoporosis, Progestin, Estrogen (Women's HOPE) study, a randomized, double-blind, placebo-controlled trial. Setting: Study centers across the United States. Patient(s): Two thousand six hundred seventy-three healthy, postmenopausalwomen. Intervention(s): Women received CEE, 0.625 mg/d: CEE, 0.625 mg/d, plus MPA2.5 mg/d; CEE, 0.45 mg/d; CEE, 0.45 mg/d, plus MPA, 2.5 mg/d; CEE 0.45 mg/d, plus MPA, 1.5 mg/d, CEE, 0.3 mg/d; CEE, 0.3 mg/d, plus MPA, 1.5 mg/d; orplacebo for 1 year. Main Outcome Measure(s): Bleeding data were analyzed in efficacy-evaluableand intention-to-treat populations. Result(s): Cumulative amenorrhea and no bleeding rates were higher with lower doses of CEE/MPA than with CEE 0.625/MPA 2.5. A linear trend between time since menopause and cumulative amenorrhea was observed (P<.05) in all CEE/MPA groups except the CEE 0.45/MPA 1.5 group. The proportion of patients who experienced no bleeding in cycle 1 was 89%, 82%, and 80% in the CEE 0.3/MPA 1.5, CEE 0.45/MPA 1.5, and CEE 0.45/MPA 2.5 groups, respectively. These values were significantly greater than the incidence of no bleeding in the CEE 0.625/MPA 2.5 group (P<.05). Conclusion(s): Lower-dose regimens of CEE and MPA produce hi,higher rates of amenorrhea and no bleeding compared with CEE 0.625/MPA 2.5 and may be appropriate for newly menopausal patients. (Fertil Steril(R) 2001;75:1080-7. (C)2001 by American Society for Reproductive Medicine.).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 01:18:01